Precision BioSciences hosts KOL event for PBGENE-DMD DMD program; no new data disclosed

PRECISION BIOSCIENCES INC

KOL event on March 17, 2026 features Dr. Veerapandiyan and Pat Furlong discussing DMD unmet need and treatment landscape.
Overview of PBGENE-DMD gene editing program and FUNCTION-DMD Phase 1/2 trial presented; no new clinical or financial data released.
Presentation materials and webcast replay available on Precision BioSciences investor website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.